SE9802974D0 - New crystalline forms - Google Patents

New crystalline forms

Info

Publication number
SE9802974D0
SE9802974D0 SE9802974A SE9802974A SE9802974D0 SE 9802974 D0 SE9802974 D0 SE 9802974D0 SE 9802974 A SE9802974 A SE 9802974A SE 9802974 A SE9802974 A SE 9802974A SE 9802974 D0 SE9802974 D0 SE 9802974D0
Authority
SE
Sweden
Prior art keywords
sub
crystalline forms
new crystalline
aze
cgl
Prior art date
Application number
SE9802974A
Other languages
English (en)
Swedish (sv)
Inventor
Lena Hedstroem
Anita Lundblad
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9802974A priority Critical patent/SE9802974D0/xx
Publication of SE9802974D0 publication Critical patent/SE9802974D0/xx
Priority to TW088114464A priority patent/TWI247013B/zh
Priority to MYPI99003779A priority patent/MY121394A/en
Priority to DE69905054T priority patent/DE69905054T2/de
Priority to US09/424,770 priority patent/US6225287B1/en
Priority to NZ524486A priority patent/NZ524486A/en
Priority to EEP200100135A priority patent/EE200100135A/xx
Priority to EP99968671A priority patent/EP1107980B1/en
Priority to DK99968671T priority patent/DK1107980T3/da
Priority to SI9930228T priority patent/SI1107980T1/xx
Priority to PL99346544A priority patent/PL346544A1/xx
Priority to PCT/SE1999/001514 priority patent/WO2000014110A1/en
Priority to AU60147/99A priority patent/AU763421B2/en
Priority to IL14143399A priority patent/IL141433A0/xx
Priority to CZ2001775A priority patent/CZ2001775A3/cs
Priority to CNB998128384A priority patent/CN1204143C/zh
Priority to SK280-2001A priority patent/SK2802001A3/sk
Priority to HK01105394.0A priority patent/HK1034721B/en
Priority to CA002341259A priority patent/CA2341259A1/en
Priority to HR20010132A priority patent/HRP20010132B1/xx
Priority to KR1020017002730A priority patent/KR100629825B1/ko
Priority to UA2001021083A priority patent/UA66869C2/uk
Priority to AT99968671T priority patent/ATE231521T1/de
Priority to ES99968671T priority patent/ES2192101T3/es
Priority to BR9913464-0A priority patent/BR9913464A/pt
Priority to CU20010061A priority patent/CU23015A3/es
Priority to TR2001/00700T priority patent/TR200100700T2/xx
Priority to EA200100194A priority patent/EA003264B1/ru
Priority to JP2000568867A priority patent/JP3493341B2/ja
Priority to IDW20010492A priority patent/ID28779A/id
Priority to ARP990104422A priority patent/AR029312A1/es
Priority to HU0104330A priority patent/HUP0104330A2/hu
Priority to OA00100056A priority patent/OA11908A/en
Priority to APAP/P/2001/002078A priority patent/AP1520A/en
Priority to YU17301A priority patent/YU17301A/sh
Priority to NZ510070A priority patent/NZ510070A/xx
Priority to SA99200682A priority patent/SA99200682B1/ar
Priority to US09/753,655 priority patent/US6440939B2/en
Priority to IS5870A priority patent/IS1942B/is
Priority to ZA200101763A priority patent/ZA200101763B/en
Priority to NO20011083A priority patent/NO20011083L/no
Priority to BG105384A priority patent/BG105384A/xx
Priority to US10/147,908 priority patent/US6888007B2/en
Priority to JP2003300959A priority patent/JP2004075687A/ja
Priority to US11/077,210 priority patent/US20050153901A1/en
Priority to US11/507,513 priority patent/US20060287249A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
SE9802974A 1998-09-03 1998-09-03 New crystalline forms SE9802974D0 (sv)

Priority Applications (46)

Application Number Priority Date Filing Date Title
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms
TW088114464A TWI247013B (en) 1998-09-03 1999-08-24 A crystalline form of compound useful in thrombin inhibitors, and the process for making the same
MYPI99003779A MY121394A (en) 1998-09-03 1999-09-01 New crystalline forms
NZ510070A NZ510070A (en) 1998-09-03 1999-09-02 Crystalline forms of EtO2 C-CH2 -(R)Cgl-Aze-Pab-OH
AT99968671T ATE231521T1 (de) 1998-09-03 1999-09-02 Kristalline formen von eto2c-ch2-(r)cgl-aze-pab- oh
ES99968671T ES2192101T3 (es) 1998-09-03 1999-09-02 Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh.
NZ524486A NZ524486A (en) 1998-09-03 1999-09-02 Method of treatment using crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
EEP200100135A EE200100135A (et) 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
EP99968671A EP1107980B1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DK99968671T DK1107980T3 (da) 1998-09-03 1999-09-02 Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
SI9930228T SI1107980T1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
PL99346544A PL346544A1 (en) 1998-09-03 1999-09-02 Crystalline forms of eto2
PCT/SE1999/001514 WO2000014110A1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
AU60147/99A AU763421B2 (en) 1998-09-03 1999-09-02 Crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
IL14143399A IL141433A0 (en) 1998-09-03 1999-09-02 Crystalline forms of eto2c-ch2- (r) cgl-aze-pab-oh
CZ2001775A CZ2001775A3 (cs) 1998-09-03 1999-09-02 Krystalické formy EtO2C-CH2-(R)Cgl-Aze-Pab-OH
CNB998128384A CN1204143C (zh) 1998-09-03 1999-09-02 EtO2C－CH2－(R)Cgl－Aze－Pab－OH的晶形
SK280-2001A SK2802001A3 (en) 1998-09-03 1999-09-02 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
HK01105394.0A HK1034721B (en) 1998-09-03 1999-09-02 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
CA002341259A CA2341259A1 (en) 1998-09-03 1999-09-02 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
HR20010132A HRP20010132B1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO<SUB>2</SUB>C-CH<SUB>2</SUB>-(R)Cgl-Aze-Pab-OH
CU20010061A CU23015A3 (es) 1998-09-03 1999-09-02 Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh.
UA2001021083A UA66869C2 (uk) 1998-09-03 1999-09-02 КРИСТАЛІЧНА ФОРМА EtO<sub>2</sub>C-CH<sub>2</sub>-(R)Cgl-Aze-Pab-OH
DE69905054T DE69905054T2 (de) 1998-09-03 1999-09-02 KRISTALLINE FORMEN VON EtO2C-CH2-(R)Cgl-Aze-Pab-OH
BR9913464-0A BR9913464A (pt) 1998-09-03 1999-09-02 Composto, processos para a produção de um composto e para a conversão de uma forma cristalina de um composto, formulação farmacêutica, uso de um composto, e, processo para tratamento de uma condição onde a inibição da trombina é requerida ou desejada
KR1020017002730A KR100629825B1 (ko) 1998-09-03 1999-09-02 ＥｔＯ2Ｃ-ＣＨ2-(Ｒ)Ｃｇｌ-Ａｚｅ-Ｐａｂ-ＯＨ의 결정질형태
US09/424,770 US6225287B1 (en) 1998-09-03 1999-09-02 Crystalline forms
TR2001/00700T TR200100700T2 (tr) 1998-09-03 1999-09-02 EtO2C--CH2-(R)Cgl-Aze-Pab-OH'nin kristalin formları
EA200100194A EA003264B1 (ru) 1998-09-03 1999-09-02 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ EtO2C-CH2-(R)Cgl-Aze-Pab-OH
JP2000568867A JP3493341B2 (ja) 1998-09-03 1999-09-02 ＥｔＯ２Ｃ−ＣＨ２−（Ｒ）Ｃｇｌ−Ａｚｅ−Ｐａｂ−ＯＨの結晶形
IDW20010492A ID28779A (id) 1998-09-03 1999-09-02 BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
ARP990104422A AR029312A1 (es) 1998-09-03 1999-09-02 Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento.
HU0104330A HUP0104330A2 (hu) 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
OA00100056A OA11908A (en) 1998-09-03 1999-09-02 Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh.
APAP/P/2001/002078A AP1520A (en) 1998-09-03 1999-09-02 Crystalline forms of EtO2C-CH2-(R)Cgl-Aze-Pab-OH
YU17301A YU17301A (sh) 1998-09-03 1999-09-02 KRISTALNI OBLICI EtO2C-CH2-(R)-Cgl-Aze-Pab-OH
SA99200682A SA99200682B1 (ar) 1998-09-03 1999-10-18 صورة متبلرة جديدة
US09/753,655 US6440939B2 (en) 1998-09-03 2001-01-04 Crystalline forms
IS5870A IS1942B (is) 1998-09-03 2001-02-28 Kristölluð form af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
ZA200101763A ZA200101763B (en) 1998-09-03 2001-03-01 Crystalline forms of Et02C-CH2-(R)Cgl-Aze-Pab-OH.
NO20011083A NO20011083L (no) 1998-09-03 2001-03-02 Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
BG105384A BG105384A (en) 1998-09-03 2001-03-26 CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH
US10/147,908 US6888007B2 (en) 1998-09-03 2002-05-20 Crystalline forms of EtO2C-Ch2-(R)Cgi-Aze-Pab-OH
JP2003300959A JP2004075687A (ja) 1998-09-03 2003-08-26 ＥｔＯ２Ｃ−ＣＨ２−（Ｒ）Ｃｇｌ−Ａｚｅ−Ｐａｂ−ＯＨの結晶形
US11/077,210 US20050153901A1 (en) 1998-09-03 2005-03-11 Crystalline forms
US11/507,513 US20060287249A1 (en) 1998-09-03 2006-08-22 Crystalline forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms

Publications (1)

Publication Number Publication Date
SE9802974D0 true SE9802974D0 (sv) 1998-09-03

Family

ID=20412468

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms

Country Status (38)

Country Link
US (5) US6225287B1 (cs)
EP (1) EP1107980B1 (cs)
JP (2) JP3493341B2 (cs)
KR (1) KR100629825B1 (cs)
CN (1) CN1204143C (cs)
AP (1) AP1520A (cs)
AR (1) AR029312A1 (cs)
AT (1) ATE231521T1 (cs)
AU (1) AU763421B2 (cs)
BG (1) BG105384A (cs)
BR (1) BR9913464A (cs)
CA (1) CA2341259A1 (cs)
CU (1) CU23015A3 (cs)
CZ (1) CZ2001775A3 (cs)
DE (1) DE69905054T2 (cs)
DK (1) DK1107980T3 (cs)
EA (1) EA003264B1 (cs)
EE (1) EE200100135A (cs)
ES (1) ES2192101T3 (cs)
HR (1) HRP20010132B1 (cs)
HU (1) HUP0104330A2 (cs)
ID (1) ID28779A (cs)
IL (1) IL141433A0 (cs)
IS (1) IS1942B (cs)
MY (1) MY121394A (cs)
NO (1) NO20011083L (cs)
NZ (2) NZ524486A (cs)
OA (1) OA11908A (cs)
PL (1) PL346544A1 (cs)
SA (1) SA99200682B1 (cs)
SE (1) SE9802974D0 (cs)
SK (1) SK2802001A3 (cs)
TR (1) TR200100700T2 (cs)
TW (1) TWI247013B (cs)
UA (1) UA66869C2 (cs)
WO (1) WO2000014110A1 (cs)
YU (1) YU17301A (cs)
ZA (1) ZA200101763B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
RU2264408C2 (ru) * 2000-10-12 2005-11-20 Чугаи Сейяку Кабусики Кайся Производное эритромицина, имеющее новые кристаллические структуры, и способы их получения
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
EP1485345B1 (de) 2002-03-11 2008-06-25 Curacyte AG Hemmstoffe der urokinase, ihre herstellung und verwendung
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US20050111007A1 (en) * 2003-09-26 2005-05-26 Zetetic Institute Catoptric and catadioptric imaging system with pellicle and aperture-array beam-splitters and non-adaptive and adaptive catoptric surfaces
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
WO2005091696A1 (en) * 2004-03-29 2005-10-06 Quanta Display Inc. A frame structure for backlight module
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
EP2361572B1 (en) * 2010-02-26 2013-04-17 Biedermann Technologies GmbH & Co. KG Implant for stabilizing bones or vertebrae
US9550585B2 (en) 2014-06-09 2017-01-24 Space Systems/Loral, Llc Highly inclined elliptical orbit de-orbit techniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075277B (it) * 1977-02-11 1985-04-22 Erba Carlo Spa Derivati insaturi e epossidici dell'acio 7-acilamido-3-cefem-4-carbossilico e procedimento per la loro preparazione
US4315011A (en) * 1978-07-12 1982-02-09 Richter Gedeon Vegyeszeti Gyar Rt. 1-Alkyl-9-bromohexahydroindolo quinolizium salts and use thereof to increase blood flow
GB2096988B (en) * 1980-11-20 1984-08-01 Beecham Group Ltd Aromatic hydroxyamines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
US5830805A (en) * 1996-11-18 1998-11-03 Cornell Research Foundation Electroless deposition equipment or apparatus and method of performing electroless deposition
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms

Also Published As

Publication number Publication date
AP1520A (en) 2005-12-28
US20030017992A1 (en) 2003-01-23
ATE231521T1 (de) 2003-02-15
AU763421B2 (en) 2003-07-24
US6225287B1 (en) 2001-05-01
ES2192101T3 (es) 2003-09-16
US20050054579A9 (en) 2005-03-10
US20010023244A1 (en) 2001-09-20
SK2802001A3 (en) 2001-09-11
NZ524486A (en) 2004-10-29
KR100629825B1 (ko) 2006-09-29
KR20010088795A (ko) 2001-09-28
IL141433A0 (en) 2002-03-10
JP2004075687A (ja) 2004-03-11
UA66869C2 (uk) 2004-06-15
EP1107980B1 (en) 2003-01-22
CN1204143C (zh) 2005-06-01
HK1034721A1 (en) 2001-11-02
JP2002524467A (ja) 2002-08-06
ZA200101763B (en) 2002-06-03
EE200100135A (et) 2002-06-17
US6440939B2 (en) 2002-08-27
DE69905054D1 (de) 2003-02-27
NO20011083L (no) 2001-05-03
IS5870A (is) 2001-02-28
NZ510070A (en) 2003-04-29
HUP0104330A2 (hu) 2002-04-29
CN1325406A (zh) 2001-12-05
DK1107980T3 (da) 2003-04-22
TWI247013B (en) 2006-01-11
US20050153901A1 (en) 2005-07-14
AU6014799A (en) 2000-03-27
BR9913464A (pt) 2001-06-12
SA99200682B1 (ar) 2006-08-22
YU17301A (sh) 2004-05-12
IS1942B (is) 2004-08-13
EA003264B1 (ru) 2003-02-27
US20060287249A1 (en) 2006-12-21
EA200100194A1 (ru) 2001-10-22
MY121394A (en) 2006-01-28
EP1107980A1 (en) 2001-06-20
CU23015A3 (es) 2005-01-25
TR200100700T2 (tr) 2001-07-23
JP3493341B2 (ja) 2004-02-03
ID28779A (id) 2001-07-05
AP2001002078A0 (en) 2001-03-31
WO2000014110A1 (en) 2000-03-16
CA2341259A1 (en) 2000-03-16
US6888007B2 (en) 2005-05-03
HRP20010132A2 (en) 2002-02-28
OA11908A (en) 2006-04-10
CZ2001775A3 (cs) 2001-10-17
BG105384A (en) 2001-11-30
NO20011083D0 (no) 2001-03-02
AR029312A1 (es) 2003-06-25
PL346544A1 (en) 2002-02-11
DE69905054T2 (de) 2003-11-06
HRP20010132B1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
SE9802974D0 (sv) New crystalline forms
CA2418614A1 (en) Phosphonocephem compound
AU7278500A (en) Fungicides
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
CA2260337A1 (en) Therapeutic agents
PT1109812E (pt) Pirrolobenzodiazepinas
AU2733997A (en) N-(amidinophenyl)-n&#39;-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SE0004245D0 (sv) Novel compounds and their use
HK1052346A1 (zh) 有效用作β-2-肾上腺素受体激动剂以及PDE4-抑制剂的化合物
AU2001266575A1 (en) Chemical compounds
DE50209545D1 (de) Flüssigkristallines medium
SE9902550D0 (sv) New crystalline forms
MY128164A (en) Compounds
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
SE9903290D0 (sv) Novel compounds
ATE263160T1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
DE60216948D1 (en) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
CA2407468A1 (en) Hydrates and crystals of a neuraminic acid compound
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DK0713485T3 (da) Thiocarbamoylforbindelser som mikrobicider
NO20021986L (no) Natrium-2-(4,6-dimetyl-pyrimidin-2-yloksy)-3-(2-(3,4- dimetoksyfenyl)etoksy)-3,3-difenylpropionat og anvendelse deravsom endothelin-antagonist
TH60760A (th) รูปแบบผลึกแบบใหม่
MX9708155A (es) Inhibicion de la fotodescomposicion de 2-oxindoles 3-sustituidos.